Cargando…

Use of Corticosteroid in Persistent Post–COVID-19 Interstitial Lung Disease

Detalles Bibliográficos
Autores principales:	Khaw, Chuen R., Richardson, Charlotte, Bhowmik, Angshu, Agbetile, Joshua, Rajakulasingam, Raja K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489875/ https://www.ncbi.nlm.nih.gov/pubmed/34191693 http://dx.doi.org/10.1513/AnnalsATS.202105-623LE

Ejemplares similares

Implementing rapid diagnostics for COVID-19
por: Nimmo, Camus, et al.
Publicado: (2021)

Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment
por: Myall, Katherine Jane, et al.
Publicado: (2021)

Benefits of Early Systemic Corticosteroid in Clinical Deterioration of Post–COVID-19 Interstitial Lung Disease
por: An, Tai Joon, et al.
Publicado: (2022)

Use of corticosteroid injections in current COVID pandemic – Time to rethink!!
por: Rajakulasingam, Ramanan, et al.
Publicado: (2020)

Severe interstitial lung disease persisting 2 years post-COVID-19 despite anti-fibrotic therapy
por: Udwadia, Zarir F., et al.
Publicado: (2022)

Persistent interstitial lung abnormalities in post-COVID-19 patients: a case series
por: Lago, Vanessa Carvalho, et al.
Publicado: (2021)

Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients
por: Morell-Hita, Jose Luis, et al.
Publicado: (2022)

Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients
por: Morell-Hita, Jose Luis, et al.
Publicado: (2022)

Nitrofurantoin induced interstitial lung disease
por: Naidu, G. D., et al.
Publicado: (2014)

Persistent Aseptic Pyelonephritis After Acute Bacterial Pyelonephritis: Possible Role of Corticosteroids
por: Tamzali, Yanis, et al.
Publicado: (2022)

No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19
por: Chan Sui Ko, Adrien, et al.
Publicado: (2022)

Corticosteroids and rehabilitation in COVID-19 survivors
por: Lal, Amos, et al.
Publicado: (2021)

Impact of late administration of corticosteroids in COVID-19 ARDS
por: Mongardon, Nicolas, et al.
Publicado: (2020)

IGRA test for TB in COVID-19: role of corticosteroids
por: Granozzi, B., et al.
Publicado: (2022)

Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease
por: Ohgushi, Migiwa, et al.
Publicado: (2021)

Lungs after COVID-19: Evolving Knowledge of Post–COVID-19 Interstitial Lung Disease
por: Aronson, Kerri I., et al.
Publicado: (2021)

A reappraisal of corticosteroids use for COVID-19
por: Pati, Ilaria, et al.
Publicado: (2022)

Post-COVID-19 interstitial lung disease presenting with profound hypoxemia: Report of three cases demonstrating a good response to high-dose corticosteroid therapy
por: Uemasu, Kiyoshi, et al.
Publicado: (2022)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
por: Wild, Jim M, et al.
Publicado: (2021)

Persistence of new-onset diabetes in the post-acute phase of COVID-19
por: Sathish, Thirunavukkarasu, et al.
Publicado: (2022)

Post-COVID Interstitial Lung Disease and Other Lung Sequelae
por: Barash, Mark, et al.
Publicado: (2023)

Mortality among Patients with COVID-19 and Different Interstitial Lung Disease Subtypes: A Multicenter Cohort Study
por: Zhao, Joy, et al.
Publicado: (2022)

Antenatal corticosteroids and COVID-19: balancing benefits and harms
por: Liauw, Jessica, et al.
Publicado: (2020)

Unresolved questions about the treatment of COVID-19 with corticosteroids()
por: Corral-Gudino, Luis, et al.
Publicado: (2021)

Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
por: Xie, Xiaohong, et al.
Publicado: (2019)

Severe chronic cough relating to post-COVID-19 interstitial lung disease: a case report
por: Nguyen-Ho, Lam, et al.
Publicado: (2022)

Post COVID Interstitial Lung Abnormalities—Incidence and Management
por: Robertshaw, Mark, et al.
Publicado: (2023)

Post-COVID Interstitial Lung Disease—The Tip of the Iceberg
por: Kewalramani, Namrata, et al.
Publicado: (2023)

Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19
por: Yuan, Lunzhi, et al.
Publicado: (2021)

Prognostic value of lymphocyte count in severe COVID-19 patients with corticosteroid treatment
por: Lu, Chenyang, et al.
Publicado: (2021)

Bullous pemphigoid triggered by COVID‐19 vaccine: Rapid resolution with corticosteroid therapy
por: Dell'Antonia, Massimo, et al.
Publicado: (2021)

Corticosteroids in H1N1, non-viral, and COVID-19 ARDS
por: Kwon, Kyoung-Eun, et al.
Publicado: (2022)

Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease
por: Fesu, Dorottya, et al.
Publicado: (2023)

Systematic MRI in persistent post‐Covid‐19 olfactory dysfunction should be reassessed
por: Brudasca, Ioana, et al.
Publicado: (2022)

Are Smoking and Vaping Risk Factors of Developing Long and Persistent Post-COVID-19?
por: de Granda-Orive, José Ignacio, et al.
Publicado: (2022)

Childhood Interstitial Lung Disease Masquerading as Post COVID-19 Respiratory Distress
por: Yavuz, Sinan, et al.
Publicado: (2021)

New therapies and management strategies in the treatment of asthma: patient-focused developments
por: Agbetile, Joshua, et al.
Publicado: (2010)

Adjuvant corticosteroid therapy for critically ill patients with COVID-19
por: Lu, Xiaofan, et al.
Publicado: (2020)

Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience
por: Adir, Yochai, et al.
Publicado: (2022)

Corticosteroids for Non-severe COVID-19: Primum Non Nocere
por: Muthu, Valliappan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ig96ek18jkiacnleurhdme37j